Following the publication of the abstract on the ESMO website, Pr.
The abstract is available on the ESMO website : https://tinyurl.com/42y4rrt6
Details of the presentation
Proffered Paper session – NSCLC, Metastatic 2
“Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of Phase 3
Presentation number: | LBA47 |
Speaker: | |
Date: | |
Lecture time: | 13:30 – |
Location: |
ABOUT
Vaccine platform
- Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive final results of the Phase 3 trial (
Atalante 1) in Non-Small CellLung Cancer patients post-ICI failure.
In Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
In Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.
In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT. - CoVepiT: a prophylactic second-generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results. Voluntary and temporary Phase 1 enrollment suspension on-going (July 2021).
- BI 765063 (OSE-172, anti-SIRPα mAb on CD47/SIRPα pathway): developed in partnership with
Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy or in combination with ezabenlimab (PD-1 antagonist); Expansion Phase 1 open for screening. - CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.
- BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.
Auto-immunity and inflammation platform
- FR104 (anti-CD28 monoclonal antibody): Licensing partnership agreement with Veloxis in the organ transplant market; ongoing Phase 1/2 in renal transplant (sponsored by the
Nantes University Hospital ); Phase 2-ready asset in an autoimmune disease indication. - OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with
Servier ; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2a is being conducted in Sjögren’s syndrome (Servier sponsor). - OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
For more information: https://ose-immuno.com/en/
Click and follow us on Twitter and Linkedln
https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673
Contacts
Sylvie Détry sylvie.detry@ose-immuno.com +33 153 198 757 Investor Relations thomas.guillot@ose-immuno.com +33 607 380 431 | Media darren@lifescicomms.com +1 646 627 8387 French Media: FP2COM fportejoie@fp2com.fr +33 607 768 283 | Advisors gvanrenterghem@lifesciadvisors.com +41 76 735 01 31 |
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of
Source:
2021 GlobeNewswire, Inc., source